Description: The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.

Description: Steris (STE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Description: Despite STERIS' outperformance relative to the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.

Description: Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see STERIS plc...

Description: Examine the evolution of Steris' (STE) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.

Description: STERIS plc recently reported strong second quarter results, with sales rising to US$1.46 billion and net income reaching US$191.9 million, both up significantly from the prior year, and confirmed its fiscal 2026 revenue growth guidance of 8-9%. The company also announced a quarterly dividend of US$0.63 per share, highlighting its continued focus on shareholder returns amid robust operating performance. We’ll now explore how STERIS’s reaffirmed revenue guidance and solid earnings growth...

Description: Steris PLC (STE) reports robust revenue growth and margin improvements, despite facing headwinds from tariffs and inflation.

Description: Shares of medical equipment and services company Steris (NYSE:STE). jumped 8.6% in the morning session after the company reported strong third-quarter 2025 results that beat expectations and raised its full-year financial outlook. For the quarter, revenues grew nearly 10% from the previous year to $1.46 billion, while adjusted earnings per share increased by 15.4% to $2.47. Both of these key figures surpassed analyst estimates. Looking ahead, STERIS provided a more optimistic forecast, lifting i

Description: STERIS posts strong Q2 results with earnings and revenue beats, margin expansion, and a raised 2026 EPS outlook.

Description: Although the revenue and EPS for Steris (STE) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Description: Steris (STE) delivered earnings and revenue surprises of +3.78% and +2.31%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Description: Medical equipment and services company Steris (NYSE:STE). reported revenue ahead of Wall Streets expectations in Q3 CY2025, with sales up 9.9% year on year to $1.46 billion. Its non-GAAP profit of $2.47 per share was 5.1% above analysts’ consensus estimates.

Description: DUBLIN (AP) — Steris Corp. STE) on Wednesday reported fiscal second-quarter net income of $191.9 million. On a per-share basis, the Dublin-based company said it had net income of $1.94.

Description: Total revenue from continuing operations increased 10%; constant currency organic revenue grew 9%As reported EPS from continuing operations increased to $1.94; adjusted EPS increased to $2.47Fiscal 2026 constant currency organic revenue, EPS and free cash flow outlook increased DUBLIN, IRELAND , Nov. 05, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced financial results for its fiscal 2026 second quarter ended September 30, 2025. Total revenue from cont

Description: Masimo (MASI) delivered earnings and revenue surprises of +10.92% and +1.34%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Description: Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Steris (STE), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2025.

Description: Medical equipment and services company Steris (NYSE:STE). will be reporting results this Wednesday after the bell. Here’s what to expect.

Description: DexCom (DXCM) delivered earnings and revenue surprises of +7.02% and +2.72%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Description: DUBLIN, IRELAND, Oct. 29, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly dividend of $0.63 per share. The dividend is payable on December 18, 2025, to shareholders of record at the close of business on November 18, 2025. Additional information about the U.S. tax treatment of dividends, including required Forms 8937, is available at www.steris-ir.com. STERIS is a leading global provider of products and servi

Description: STERIS (STE) has drawn attention recently as its stock performance continues to stand out, particularly in comparison with the broader healthcare sector. Investors are watching closely to see how the company's consistent growth translates into future value. See our latest analysis for STERIS. STERIS’s share price has seen solid momentum this year, up nearly 19.5% year-to-date, with the latest close at $241.85. That momentum is backed by a 7.5% total return over the last twelve months and an...

Description: Upslope Capital Management, an investment management company, released its third-quarter investor letter. A copy of the letter can be downloaded here. The third quarter was a strong one for the fund despite unusual volatility in the macro environment. The fund returned +8.8% (net) in Q3 compared to +5.5% and +3.8% for the S&P Midcap 400 […]

Description: Even though STERIS (currently trading at $242.37 per share) has gained 8.3% over the last six months, it has lagged the S&P 500’s 24.7% return during that period. This might have investors contemplating their next move.

Description: STE is set to post fiscal Q2 results on Nov. 6, with estimates pointing to solid revenue and earnings growth across key segments.

Description: STERIS is scheduled to release its second-quarter results next month, and analysts are anticipating a robust double-digit increase in earnings.

Description: DUBLIN, IRELAND, Oct. 21, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2026 second quarter results at 9:00 a.m. ET on November 6, 2025. The conference call can be heard live at www.steris-ir.com or via phone by dialing 1-800-715-9871 in the United States or 1-646-307-1963 internationally, then asking to join the conference call for STERIS plc. A press release detailing financial results will